The Impact of the Entry of Biosimilars: Evidence From Europe

Review of Industrial Organization - Netherlands
doi 10.1007/s11151-018-9630-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Impact of Institutional Distance on the Choice of Multinational Enterprise’s Entry Mode: Theory and Empirical Evidence From Vietnam

Asian Journal of Business and Accounting
AccountingInternational ManagementBusiness
2018English

Biologicals and Biosimilars: Safety Issues in Europe

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2017English

The Structure of the Permanent Job Wage Premium: Evidence From Europe

Industrial Relations
Industrial RelationsManagementOrganizational BehaviorHuman Resource ManagementStrategyInnovationManagement of Technology
2015English

Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence

BioDrugs
MedicineBiotechnologyPharmacology
2017English

Switching From Originator Biological Agents to Biosimilars: What Is the Evidence and What Are the Issues?

RMD Open
RheumatologyAllergyImmunology
2017English

Disentangling the Effects of State Ownership on Investment Evidence From Europe

SSRN Electronic Journal
2016English

Patient Choice, Entry, and the Quality of Primary Care: Evidence From Swedish Reforms

Health Economics
Health Policy
2020English

Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

BioDrugs
MedicineBiotechnologyPharmacology
2016English

The Impact of Age of Entry on Academic Progression

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy